Fulcrum Metals boost Saskatchewan uranium exploration assets by 221% to 59,000 acres. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Regulatory News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.25
Bid: 2.10
Ask: 2.40
Change: 0.20 (9.76%)
Spread: 0.30 (14.286%)
Open: 2.05
High: 2.30
Low: 2.05
Prev. Close: 2.05
CIZ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Put Option with Conduit

21 Sep 2023 07:00

RNS Number : 1933N
Cizzle Biotechnology Holdings PLC
21 September 2023

21 September 2023

Cizzle Biotechnology Holdings plc


("Cizzle" or "the Company")


Update on Put Option with Conduit

Shareholder Approval for Conduit-Murphy Merger and NASDAQ Listing

Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, announces a further update regarding the Company's put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat inflammatory pulmonary and cardiovascular disease ("Option") to Conduit Pharmaceuticals ("Conduit") for a total consideration of £3.25 million, to be satisfied through the issuance of new shares in Conduit (the "Option") and its prospective parent Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy").


Cizzle announced on 8 September that 2023 that Murphy planned to hold a special meeting of its shareholders to provide their approval for the merger of Conduit and Murphy on Wednesday 20 September 2023. At the meeting held yesterday the merger was approved and as a consequence it is expected to complete today.  Assuming the merger completes as expected, the Conduit-Murphy merged business, thereafter to be called Conduit, will become a publicly traded company on NASDAQ in the USA tomorrow, 22 September 2023.


Should Cizzle exercise its Option, the Company will hold shares in the NASDAQ listed merged business. The new shares in Conduit to be provided to Cizzle pursuant to the exercise of the Option will not be subject to any restrictions.




Cizzle Biotechnology Holdings plc

Via IFC Advisory

Allan Syms (Executive Chairman)


Allenby Capital Limited

+44(0) 20 3328 5656

John Depasquale

George Payne


Novum Securities Limited

+44(0) 20 7399 9400

Colin Rowbury

Jon Bellis


IFC Advisory Limited

+44(0) 20 3934 6630

Tim Metcalfe

Florence Chandler


About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

About Conduit Pharmaceuticals Limited

Led by highly experienced pharma executives, Conduit is a clinical stage specialty biopharmaceutical company, addressing unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. The development pipeline includes a glucokinase inhibitor in a number of Phase 2 ready autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant. Conduit's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
28th Sep 20237:00 amRNSInterim Results
21st Sep 20237:00 amRNSUpdate on Put Option with Conduit
19th Sep 20237:00 amRNSCompletion of Evaluation Programme with Bio-Techne
8th Sep 20237:03 amRNSExtension of and update on Put Option with Conduit
15th Aug 20237:00 amRNSUpdate on Put Option with Conduit
10th Aug 20237:00 amRNSExpansion of Research Agreement and CIZ1B Update
30th Jun 20235:00 pmRNSTotal Voting Rights
28th Jun 202312:01 pmRNSResult of AGM
12th Jun 20232:15 pmRNSTotal Voting Rights
12th Jun 20237:00 amRNSSubscription to raise £350,000
5th Jun 202312:35 pmRNSPosting of Annual Report and Notice of AGM
15th May 20231:42 pmRNSUpdate on Royalty Sharing Agreement in AZD1656
27th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Apr 20237:00 amRNSNew Research Agreement with the University of York
30th Mar 202311:05 amRNSSecond Price Monitoring Extn
30th Mar 202311:00 amRNSPrice Monitoring Extension
17th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSIssue of Options in lieu of salary increases
22nd Feb 20237:52 amRNSHolding(s) in Company
6th Feb 20237:02 amRNSHolding(s) in Company
31st Jan 20235:00 pmRNSTotal Voting Rights
24th Jan 202312:48 pmRNSHolding(s) in Company
20th Dec 20223:17 pmRNSUpdate re. timing of Admission
19th Dec 20227:00 amRNSPut Option re AZD1656 & £115,586 Subscription
23rd Nov 20228:04 amRNSClinical Study for Lung Cancer Detection in China
9th Nov 20227:00 amRNSConduit Pharmaceuticals Proposed Listing
31st Oct 20225:00 pmRNSTotal Voting Rights
4th Oct 20228:00 amRNSAdmission and Total Voting Rights
30th Sep 20225:00 pmRNSTotal Voting Rights
29th Sep 20223:49 pmRNSIssue of Consideration Shares & Option Exercise
28th Sep 20223:05 pmRNSHolding(s) in Company
28th Sep 20227:00 amRNSInterim results
26th Sep 20228:00 amRNSAdmission and Total Voting Rights
21st Sep 202211:23 amRNSSubscription, Facility & Publication of Prospectus
18th Aug 20229:21 amRNSArcadia Clinical Trial Results Published
10th Aug 20224:41 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Jul 20227:15 amEQSHardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progress in first year since listing
5th Jul 20227:00 amRNSUpdate on Development of Proprietary Antibodies
27th Jun 202211:52 amRNSResult of AGM
16th Jun 20227:00 amRNSMarketing Agreement to Enhance Expansion in the US
1st Jun 20227:00 amRNSPosting of Annual Report and Notice of AGM
30th May 20227:00 amRNSResults for the year ended 31 December 2021
6th May 20229:05 amRNSSecond Price Monitoring Extn
6th May 20229:00 amRNSPrice Monitoring Extension
6th May 20227:00 amRNSStrategic Alliance re lung cancer detection in USA
11th Apr 20227:00 amRNSFurther Research Agreement with University of York
31st Mar 20225:28 pmRNSHolding(s) in Company
22nd Mar 20224:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.